Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
E. Domènech, M. Esteve-Comas, F. Gomollón, J. Hinojosa, A. Obrador, J. Parés, et al.
Recomendaciones para el uso de infliximab (Remicade) en la enfermedad de Crohn. GETECCU 2001.
Gastroenterol Hepatol, 25 (2002), pp. 162-169
[2.]
S.R. Targan, S.B. Hanauer, S.J. Van Eventer, L. Mayer, D.H. Present, T. Braakman, et al.
A Short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.
N Engl J Med, 337 (1997), pp. 1029-1035
[3.]
G.R. Lichtenstein.
Is Infliximab effective for induction of remission in patientes with ulcerative colitis.
Inflamm Bowel Dis, 7 (2001), pp. 89-93
[4.]
B.E. Sands.
Therapy of inflammatory bowel disease.
Gastroenterology, 118 (2000), pp. S68-S82
[5.]
W.Y. Chey.
Infliximab for patients with refractory ulcerative colitis.
Inflamm Bowel Dis, 7 (2001), pp. S30-S33
[6.]
W.Y. Chey, A. Hussain, C. Ryan, G.D. Potter, A. Shah.
Infliximab for refractory ulcerative colitis.
Am J Gastroenterol, 96 (2001), pp. 2373-2381
[7.]
Sands BE, Tremaine WJ, Sandborn WJ, Rutgeets PJ, Hanauer SB, Mayer LM, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 7;2:83-8
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
